Neurocrine legal chief sells 10,000 shares at $179

Neurocrine Biosciences Inc. Chief Legal Officer Darin Lippoldt reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share.

Rhea-AI Filing Summary

Neurocrine Biosciences Inc. Chief Legal Officer Darin Lippoldt reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, with individual trade prices ranging from $179.50 to $179.80.

On the same date, Lippoldt also exercised non-qualified stock options covering 10,000 shares of common stock at an exercise price of $81.49 per share, reducing the reported option balance to 4,965 options on this grant. These options were granted on February 5, 2018, vested in 48 equal monthly installments beginning March 5, 2018, and are scheduled to expire on February 5, 2028.

Filing Explained

The July 9 filing records an officer’s option exercise and matched sale, changing his holdings without disclosing an issuer-level change for common holders.

Darin Lippoldt, Neurocrine Biosciences’ Chief Legal Officer, reported on July 13, 2026 that he exercised an option for 10,000 common shares and sold 10,000 common shares on July 9, 2026; the disclosed effect is on his holdings, not an issuer-level transaction for existing common holders.

Under Form 4 codes, M identifies an option or derivative exercise and S identifies an open-market sale. The filing says the sale was executed by a broker under a Rule 10b5-1 plan adopted on June 9, 2025, and that issuer policy prohibits later amendment or modification of that plan.

After the exercise, his directly held common stock was reported at 64,729 shares; after the sale, it was reported at 54,729 shares, while 4,965 options remained directly held. The sale price was a weighted average of $179.6014 per share, with individual sale prices ranging from $179.50 to $179.80.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($981K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Lippoldt Darin

Role Chief Legal Officer

Sold 10,000 shs ($1.80M)

Approx. gross sale proceeds $1.80M

Approx. exercise cost $815K

Approx. pre-tax spread $981K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option F3	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$81.49	$815K
Sale	Common Stock F1, F2	10,000	$179.6014	$1.80M

Holdings After Transaction: Non-Qualified Stock Option — 4,965 contracts (Direct); Common Stock — 54,729 shares (Direct)

Footnotes (3)

1. F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 04:27 PM Accepted by SEC EDGAR 07/13/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippoldt Darin

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M		10,000	A	$81.49	64,729	D
Common Stock	07/09/2026		S(1)		10,000	D	$179.6014(2)	54,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$81.49	07/09/2026		M			10,000	(3)	02/05/2028	Common Stock	10,000	$0	4,965	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $179.50 to $179.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

Remarks:

	/s/ Darin Lippoldt	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)